Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Cartesian Therapeutics ( (RNAC) ) has issued an announcement.
Cartesian Therapeutics recently announced its strategic priorities for 2025, including the advancement of its mRNA CAR-T cell therapy, Descartes-08, which is under clinical evaluation for myasthenia gravis and other autoimmune diseases. With a strong balance sheet, the company plans to commence a Phase 3 trial for Descartes-08 in the first half of 2025, highlighting its commitment to addressing significant unmet medical needs in the autoimmune space.
More about Cartesian Therapeutics
Cartesian Therapeutics, Inc. is a clinical-stage company pioneering mRNA cell therapies aimed at expanding the use of cell therapy for autoimmune diseases. Their pipeline includes investigational products such as Descartes-08 and Descartes-15, designed for outpatient administration without lymphodepletion, targeting conditions like myasthenia gravis and systemic lupus erythematosus.
YTD Price Performance: -0.53%
Average Trading Volume: 122,133
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $433.2M
See more insights into RNAC stock on TipRanks’ Stock Analysis page.
